Literature DB >> 10199474

Natural history of urothelial dysplasia of the bladder.

L Cheng1, J C Cheville, R M Neumann, D G Bostwick.   

Abstract

Urothelial dysplasia is the putative precursor of urothelial carcinoma in situ (CIS) and invasive urothelial carcinoma of the urinary tract. Urothelial dysplasia is frequently identified in patients with urothelial CIS and cancer. However, very little is known about the clinical presentation and natural history of urothelial dysplasia in the absence of urothelial CIS or invasive cancer. The authors studied 36 patients with isolated urothelial dysplasia at the Mayo Clinic between 1969 and 1984. None of these patients had previous or concurrent urothelial CIS or invasive cancer, and none received treatment for dysplasia. The histopathologic features of urothelial dysplasia were examined, and long-term clinical follow-up was obtained. Progression was defined as the development of urothelial CIS or carcinoma. The male-to-female ratio was 2.6:1, and the mean patient age at the time of diagnosis was 60 years (range 25-79). Urothelial dysplasia has a predilection for the posterior wall. Eleven patients had urinary irritative symptoms, 10 had hematuria, 3 had both irritative symptoms and hematuria, and 12 were found to have dysplasia incidentally. The mean follow-up was 8.2 years (range 0.1-25.5). Seven (19%) of 36 patients developed biopsy-proven progression, including 4 with CIS and 3 with invasive cancer, and 1 of them died of bladder cancer. The intervals from diagnosis to progression ranged from 6 months to 8 years (mean 2.5 years). One of the remaining 29 patients had positive cytologic results 2.5 years after the initial diagnosis of dysplasia. The authors conclude that urothelial dysplasia is a significant risk for the development of CIS and invasive urothelial carcinoma, and patients with urothelial dysplasia should be followed up closely.

Entities:  

Mesh:

Year:  1999        PMID: 10199474     DOI: 10.1097/00000478-199904000-00009

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

1.  Early detection of urothelial premalignant lesions using hexaminolevulinate fluorescence cystoscopy in high risk patients.

Authors:  Salvatore Blanco; Marco Raber; Biagio Eugenio Leone; Luca Nespoli; Marco Grasso
Journal:  J Transl Med       Date:  2010-11-22       Impact factor: 5.531

2.  Diagnostically challenging cases: what are atypia and dysplasia?

Authors:  Joseph Sanfrancesco; J Stephen Jones; Donna E Hansel
Journal:  Urol Clin North Am       Date:  2013-02-26       Impact factor: 2.241

Review 3.  [Urinary bladder tumours. The new 2004 WHO classification].

Authors:  M Seitz; D Zaak; R Knüchel-Clarke; C Stief
Journal:  Urologe A       Date:  2005-09       Impact factor: 0.639

4.  Hemobilia due to biliary intraepithelial neoplasia associated with Zollinger-Ellison syndrome.

Authors:  Rumiko Umeda; Yuji Nakamura; Yohei Masugi; Masahiro Shinoda; Naoki Hosoe; Yoshihiro Ono; Tomonori Fujimura; Yoshiyuki Yamagishi; Hajime Higuchi; Hirotoshi Ebinuma; Shigenari Hozawa; Minoru Tanabe; Subaru Hashimoto; Michiie Sakamoto; Yuko Kitagawa; Toshifumi Hibi
Journal:  Clin J Gastroenterol       Date:  2012-04-21

5.  Uroplakin 1b is critical in urinary tract development and urothelial differentiation and homeostasis.

Authors:  Ashley R Carpenter; M Brian Becknell; Christina B Ching; Edward J Cuaresma; Xi Chen; David S Hains; Kirk M McHugh
Journal:  Kidney Int       Date:  2015-12-23       Impact factor: 10.612

Review 6.  Role of renal urothelium in the development and progression of kidney disease.

Authors:  Ashley R Carpenter; Kirk M McHugh
Journal:  Pediatr Nephrol       Date:  2016-04-26       Impact factor: 3.714

Review 7.  [Urine-based tumour diagnostics for bladder cancer: effects of the new histopathological classification--food for thought].

Authors:  R Knüchel; K Lindemann-Docter
Journal:  Urologe A       Date:  2009-06       Impact factor: 0.639

8.  Toxicological evaluation of subchronic use of pioglitazone in mice.

Authors:  Said Said Elshama; Ayman El-Meghawry El-Kenawy; Hosam-Eldin Hussein Osman
Journal:  Iran J Basic Med Sci       Date:  2016-07       Impact factor: 2.699

9.  CD10 expression in urothelial carcinoma of the bladder.

Authors:  Burak Bahadir; Kemal Behzatoglu; Sibel Bektas; Erol R Bozkurt; Sukru O Ozdamar
Journal:  Diagn Pathol       Date:  2009-11-16       Impact factor: 2.644

10.  Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies.

Authors:  Isil Z Yildiz; Rosemary Recavarren; Henry B Armah; Sheldon Bastacky; Rajiv Dhir; Anil V Parwani
Journal:  Diagn Pathol       Date:  2009-10-14       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.